Functional analysis of three CYP1A2 variants found in a Japanese population

Drug Metabolism and Disposition

Volumn 33, Issue 12, 2005, Pages 1905-1910

  Saito, Yoshiro ^a   Hanioka, Nobumitsu ^b   Maekawa, Keiko ^a   Isobe, Takashi ^b   Tsuneto, Yumi ^b   Nakamura, Ryosuke ^a   Soyama, Akiko ^a   Ozawa, Shogo ^a   Tanaka Kagawa, Toshiko ^a   Jinno, Hideto ^a   Narimatsu, Shizuo ^b   Sawada, Jun Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHOXYRESORUFIN O DEETHYLATION; AMINO ACID; ARGININE; CYTOCHROME P450 1A2; ENZYME VARIANT; GLUTAMINE; HEMOPROTEIN; HISTIDINE; HOLOENZYME; MESSENGER RNA; PHENACETIN O DEETHYLASE; PROLINE; RECOMBINANT PROTEIN; RESORUFIN DERIVATIVE; UNCLASSIFIED DRUG; WT1 PROTEIN;

ANIMAL CELL; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL STRAIN V 79; CHINESE HAMSTER; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; FUNCTIONAL ASSESSMENT; JAPAN; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; SPECTROSCOPY; STATISTICAL SIGNIFICANCE; WILD TYPE;

ANIMALS; CELL LINE; CRICETINAE; CRICETULUS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; HUMANS; POLYMORPHISM, GENETIC; SPODOPTERA;

ANIMALIA; CRICETULUS GRISEUS;

EID: 28144435129     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.005819     Document Type: Article

References (35)

1. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, and Ingelman-Sundberg M (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64:659-669.
2. Allorge D, Chevalier D, Lo-Guidice JM, Cauffiez C, Suard F, Baumann P, Eap CB, and Broly F (2003) Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol 56:341-344.
3. Chen CD, Doray B, and Kemper B (1998) A conserved proline-rich sequence between the N-terminal signal-anchor and catalytic domains is required for assembly of functional cytochrome P450 2C2. Arch Biochem Biophys 350:233-238.
4. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, and Guengerich FP (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057-9067.
5. Eaton DL, Gallagher EP, Bammler TK, and Kunze KL (1995) Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5:259-274.
6. Fuhr U, Doehmer J, Battula N, Wolfel C, Kudla C, Keita Y, and Staib AH (1992) Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol 43:225-235.
7. Furuya H, Shimizu T, Hatano M, and Fujii-Kuriyama Y (1989a) Mutations at the distal and proximal sites of cytochrome P-450d changed regio-specificity of acetanilide hydroxylations. Biochem Biophys Res Commun 160:669-676.
8. Furuya H, Shimizu T, Hirano K, Hatano M, Fujii-Kuriyama Y, Raag R, and Poulos TL (1989b) Site-directed mutageneses of rat liver cytochrome P-450d: catalytic activities toward benzphetamine and 7-ethoxycoumarin. Biochemistry 28:6848-6857.
9. Glatt H, Gemperlein I, Setiabudi F, Platt KL, and Oesch F (1990) Expression of xenobiotic-metabolizing enzymes in propagatable cell cultures and induction of micronuclei by 13 compounds. Mutagenesis 5:241-249.
10. Gonzalez FJ, Kimura S, Tamura S, and Gelboin HV (1991) Expression of mammalian cytochrome P450 using baculovirus. Methods Enzymol 206:93-99.
11. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
12. Guengerich FP, Parikh A, Turesky RJ, and Josephy PD (1999) Inter-individual differences in the metabolism of environmental toxicants: cytochrome P450 1A2 as a prototype. Mutat Res 428:115-124.
13. Hanioka N, Ozawa S, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M, and Sawada J (2002) Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzyme. Drug Metab Dispos 30:391-396.
14. Hanioka N, Tatarazako N, Jinno H, Arizono K, and Ando M (2000) Determination of cytochrome P450 1A activities in mammalian liver microsomes by high-performance liquid chromatography with fluorescence detection. J Chromatogr B 744:399-406.
15. Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA, and Deisenhofer J (1995) Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 3:41-62.
16. Huang JD, Guo WC, Lai MD, Guo YL, and Lambert GH (1999) Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 27:98-101.
17. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, and Kimura S (1989) Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene and differences in liver 1A2 mRNA expression. Mol Endocrinol 3:1399-1408.
18. Iwasaki M, Yoshimura Y, Asahi S, Saito K, Sakai S, Morita S, Takenaka O, Inoda T, Kashiyama E, Aoyama A, et al. (2004) Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6 and CYP2B6 found in the Japanese population. Drug Metab Pharmacokinet 19:444-452.
19. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, and Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459.
20. Kagimoto M, Heim M, Kagimoto K, Zeugin T, and Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-17214.
21. Kemper B (2004) Structural basis for the role in protein folding of conserved proline-rich regions in cytochromes P450. Toxicol Appl Pharmacol 199:305-315.
22. Kendler KS and Prescott CA (1999) Caffeine intake, tolerance and withdrawal in women: a population-based twin study. Am J Psychiatry 156:223-228.
23. Lewis DF (2001) Guide to Cytochrome P450: Structure and Function. Taylor & Francis, New York.
24. Lewis DF, Lake BG, Dickins M, Ueng YF, and Goldfarb PS (2003) Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure. Xenobiotica 33:239-254.
25. Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kimura H, Goto Y, et al. (2004) Six novel non-synonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. [published erratum appears in J Pharmacol Exp Ther (2004) 308:1219] J Pharmacol Exp Ther 308:300 -306.
26. Nakajima M, Kobayashi K, Shimada N, Tokudome S, Yamamoto T, and Kuroiwa Y (1998) Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol 46:55-62.
27. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, and Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125:803-808.
28. Nakamura K, Ariyoshi N, Yokoi T, Ohgiya S, Chida M, Nagashima K, Inoue K, Kodama T, Shimada N, and Kamataki T (2002) CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem Biophys Res Commun 293:969-973.
29. Rasmussen BB, Brix TH, Kyvik KO, and Brosen K (2002) The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12:473-478.
30. Sachse C, Brockmoller J, Bauer S, and Roots I (1999) Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449.
31. Sarkar MA and Jackson BJ (1994) Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab Dispos 22:827-834.
32. Saruwatari J, Nakagawa K, Shindo J, Tajiri T, Fujieda M, Yamazaki H, Kamataki T, and Ishizaki T (2002) A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther 72:200-208.
33. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
34. Soyama A, Saito Y, Hanioka N, Maekawa K, Komamura K, Kamakura S, Kitakaze M, Tomoike H, Ueno K, Goto Y, et al. (2005) Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. [published erratum appears in Drug Metab Pharmacokinet (2005) 20:152] Drug Metab Pharmacokinet 20:24-33.
35. Zhou H, Josephy PD, Kim D, and Guengerich FP (2004) Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch Biochem Biophys 422:23-30.